Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways
to stop the growth of cancer cells, either by killing the cells or by stopping them from
dividing. Ascorbic acid may help melphalan work better by making cancer cells more sensitive
to the drug. Giving bortezomib together with ascorbic acid and melphalan may kill more cancer
cells.
PURPOSE: This phase II trial is studying how well giving bortezomib together with ascorbic
acid and melphalan works in treating patients with newly diagnosed multiple myeloma.